recorded webinar

Medical Marijuana Laws & Evidence for Harmful/Beneficial Effects in Depression and Anxiety Disorders

Medical Marijuana Laws & Evidence for Harmful/Beneficial Effects in Depression and Anxiety Disorders
Thursday, May 28, 2020 1:00 pm
- 2:00 pm ET

Member Prices


As of February 2020, “medical marijuana” has been approved in 33 states, District of Columbia, Guam, Puerto Rico and US Virgin Islands in the US and Canada. Additionally 14 states and territories have approved recreational adult-use of marijuana. Marijuana, however remains a Schedule-1 drug per the US Drug Enforcement Administration (DEA). Nevertheless, today the market-place is flooded with over 2500 “strains” of the marijuana plant and marijuana-infused products (including edibles, concentrates, dabs, waxes, oils, vaping fluids). These products are not regulated by the Food and Drug Administration (FDA) and don’t meet the FDA standards for approval of other medications, although the product labels accompanying these products may appear similar to that seen with pharmaceutical medications. 

Evidence supporting the use of “medical marijuana” for specific medical conditions is of low quality at the present time. Furthermore, individuals with certain psychiatric disorders may be at greater risk for adverse effects. This presents a challenge for physicians treating patients who use “medical marijuana” and tout the benefits of the products based on manufacturer’s product labels. Furthermore, it is possible that psychiatrists encounter patients who are using medical marijuana for a psychiatric indication or may be co-managing a patient who is receiving medical marijuana for a no psychiatric (medical) condition. Patients also often echo ill-informed counter-arguments against the scientific evidence, making it important for physicians to keep up-to-date with scientific literature on the topic.

This webinar provides practitioners with an update on marijuana laws in the US and the evidence for the use of ‘medical marijuana’ as a treatment for anxiety disorders. Dr. Kevin Sebat provides an overview of marijuana laws in the US, and the provisions under decriminalization vs legalization, use for “medical” purposes vs recreational use. Dr. Rajiv Radhakrishnan provides an update on the evidence for harmful/beneficial effects of medical marijuana in anxiety disorders (including PTSD).

Learning Objectives:

  1. Provide an overview of laws governing the use of “medical marijuana” in different states in the US.
  2. Provide an update on the evidence for harmful and beneficial effects of medical marijuana in anxiety disorders and PTSD 
  3. Provide an update on the evidence for harmful and beneficial effects of CBD in anxiety disorders and PTSD 


Presenter(s) Biography

Rajiv Radhakrishnan MBBS, MD

Rajiv Radhakrishnan MBBS, MD

Dr. Rajiv Radhakrishnan MBBS, MD is an Assistant Professor of Psychiatry at Yale University School of Medicine. He is board-certified in Psychiatry and Addiction Medicine. As a physician-scientist with a research interest in examining the effects of cannabinoids, he has conducted laboratory studies using THC and is currently examining the effects of cannabidiol on brain microglial activation using PET imaging in a NIH-funded study. Dr. Radhakrishnan has published papers on the evidence for the use of medical marijuana in psychiatric disorders and what clinicians need to know about the topic.


Kevin A. Sabet, PhD

Kevin Sabet, PhD

Kevin A. Sabet, PhD., President & CEO Smart Approaches to Marijuana

Described by NBC as the “prodigy” of drug politics and policy, Kevin A. Sabet, PhD, is an author, consultant, former advisor to three U.S. presidential administrations, assistant professor, and serves as the President and CEO of SAM, which he founded with former Congressman Patrick Kennedy in 2013. He has studied, researched, written about, and implemented drug policy for almost 20 years. He has worked in the Clinton (2000), Bush (2002-2003) Administrations, and in 2011 he stepped down after serving more than two years as the senior advisor to President Obama’s drug control director, having been the only drug policy staffer to have ever served as a political appointee in a Democrat and Republican administration. He has appeared since at the Aspen Ideas and New Yorker festivals, on the Organization of American States blue ribbon commission advising hemispheric drug policy, and in hundreds of forums and discussions promoting the ideas outlined in his first book, Reefer Sanity: Seven Great Myths About Marijuana, published by Beaufort. He has been featured on the front page of the New York Times and in virtually every major media publication and news channel on the subject of drug policy.

Professional Post

ADAA Continuing Education Credits for Live and On-Demand Programming

Learners complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Some ADAA professional webinars focused on diversity or cultural competency subject matter are eligible for the Cross-Culture Competency Diversity Credit. If a webinar is eligible for this credit, it will be reflected on your credit certificate.

All continuing education credits are provided through Amedco, LLC. Learn more about the CE/CME accreditation information here.